Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Biliary Tract Cancer × sitravatinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 4 Carcinoma, Non-Small-Cell Lung 4 Triple Negative Breast Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Prostatic Neoplasms 1 Neoplasms 1 Metastatic Non-Squamous Non-Small Cell Lung Cancer 1 Melanoma 1 Lung Neoplasms 1 Liposarcoma 1 Head and Neck Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma 1 Advanced or Metastatic Solid Malignancies 1 Advanced Solid Tumors 1 Advanced Solid Tumor 1 Advanced Malignancies 1 Advanced Biliary Tract Cancer 1 Adenocarcinoma 1

Interventions

lenvatinib 3 tislelizumab 2 sintilimab 2 Gemcitabine 2 Cisplatin 2 toripalimab 1 theasinensin A 1 sitravatinib 1 pembrolizumab 1 durvalumab 1 S 1 (combination) 1 Injections 1 Folfox protocol 1 Fluorouracil 1 Cryosurgery 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04727996 2024-04-19

BTC-BGB

Seoul National University Hospital

Phase 2 Active not recruiting

Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡